Approved delivery strategies for biopharmaceuticals  

作　　者：Makhloufi Zoulikha Zhongjian Chen Jun Wu Wei He 

机构地区：[1]School of Pharmacy,China Pharmaceutical University,Nanjing 2111198,China [2]Shanghai Skin Disease Hospital,Tongji University School of Medicine,Shanghai 200443,China [3]Department of Geriatric Cardiology,Jiangsu Provincial Key Laboratory of Geriatrics,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China

出　　处：《Chinese Chemical Letters》2025年第2期41-51,共11页中国化学快报(英文版)

基　　金：supported by the National Natural Science Foundation of China(Nos.82073782 and 82241002);the Natural Science Foundation of the Jiangsu Higher Education Institutions of China(No.21KJA320003);the Scientific Research Project of Jiangsu Commission of Health(No.LKZ2023001)。

摘　　要：In recent years,biopharmaceuticals have witnessed remarkable advancements,transforming the landscape of therapeutic interventions.Biopharmaceuticals encompassing therapeutics generated through cutting-edge biotechnological methods have shown promising therapeutic outcomes.However,their clinical success hinges significantly on overcoming drug delivery challenges related to stability,intracellular delivery,immunogenicity,and pharmacokinetic properties.Herein,we provide an overview of various marketed macromolecules,including nucleic acids,and immunotherapeutic agents such as cytokines and monoclonal antibodies,as well as other therapeutic peptides/proteins like enzymes,hormones,and coagulation factors.Our primary focus is on elucidating the delivery challenges associated with these macromolecules and highlighting the pivotal role played by drug delivery platforms in the development of currently marketed products,offering valuable insights for both scientific research and the pharmaceutical industry.

关 键 词：BIOPHARMACEUTICALS Nucleic acids Monoclonal antibodies PROTEINS Drug delivery 

分 类 号：R943[医药卫生—药剂学]